Figure 2: Validation of FAM83H-AS1 expression in an independent cohort of LUADs by qRT-PCR. | Scientific Reports

Figure 2: Validation of FAM83H-AS1 expression in an independent cohort of LUADs by qRT-PCR.

From: Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer

Figure 2

(A–C) validation of FAM83H-AS1 expression in an independent set of samples including 19 normal lung tissues and 101 LUAD tissues using qRT-PCR. FAM83H-AS1 expression was increased in tumors (vs. normal, **p < 0.001) (A), ROC curve of classifying the tumors from normal based on FAM83H-AS1 expression (AUC = 0.87) (B), and Kaplan-Meier survival curve indicated higher FAM83H-AS1 expression was unfavorable for patient survival (log-rank test, p = 0.008) (C). (D) Higher expression (FRKM log2 value > 2) of FAM83H-AS1 was also present in squamous cell (LUSC) and large cell lung cancer (LULC), as well as bladder, breast, gastric, head/neck, and prostate cancers, whereas lower expression was present in kidney, liver, and thyroid cancers (FRKM log2 value < 2) based on RNA-Seq expression data from MiTranscriptome. *Tumor vs. normal, p < 0.05.

Back to article page